Corebridge Financial Inc. Lowers Stock Holdings in Encompass Health Co. (NYSE:EHC)

Corebridge Financial Inc. reduced its stake in Encompass Health Co. (NYSE:EHC) by 4.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 113,989 shares of the company’s stock after selling 4,992 shares during the quarter. Corebridge Financial Inc.’s holdings in Encompass Health were worth $10,527,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in EHC. Miracle Mile Advisors LLC boosted its holdings in Encompass Health by 3.0% in the fourth quarter. Miracle Mile Advisors LLC now owns 3,835 shares of the company’s stock worth $354,000 after acquiring an additional 112 shares in the last quarter. US Bancorp DE raised its position in shares of Encompass Health by 9.6% in the 4th quarter. US Bancorp DE now owns 1,380 shares of the company’s stock worth $127,000 after purchasing an additional 121 shares during the last quarter. Signaturefd LLC boosted its stake in Encompass Health by 21.6% in the 4th quarter. Signaturefd LLC now owns 704 shares of the company’s stock worth $65,000 after purchasing an additional 125 shares in the last quarter. CBIZ Investment Advisory Services LLC grew its position in Encompass Health by 38.7% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock valued at $42,000 after purchasing an additional 127 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its stake in Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after purchasing an additional 137 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Performance

EHC opened at $100.33 on Thursday. Encompass Health Co. has a 12-month low of $77.09 and a 12-month high of $104.55. The company has a market cap of $10.10 billion, a price-to-earnings ratio of 22.50, a PEG ratio of 2.31 and a beta of 0.92. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84. The company’s 50 day moving average is $98.42 and its 200 day moving average is $97.29.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. On average, equities research analysts predict that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.68%. Encompass Health’s payout ratio is currently 15.25%.

Insider Activity at Encompass Health

In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the transaction, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. This represents a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

EHC has been the topic of a number of recent analyst reports. William Blair reiterated an “outperform” rating on shares of Encompass Health in a report on Friday, February 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $110.00 target price on shares of Encompass Health in a research note on Tuesday, February 11th. KeyCorp boosted their price target on Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. StockNews.com raised Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, February 15th. Finally, Barclays boosted their target price on Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Ten investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Encompass Health currently has an average rating of “Buy” and a consensus target price of $107.67.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.